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Abstract
Background: Poor recruitment and retention of participants in randomised controlled trials
(RCTs) is problematic but common. Clear and detailed reporting of participant flow is essential to
assess the generalisability and comparability of RCTs. Despite improved reporting since the
implementation of the CONSORT statement, important problems remain. This paper aims: (i) to
update and extend previous reviews evaluating reporting of participant recruitment and retention
in RCTs; (ii) to quantify the level of participation throughout RCTs.
Methods: We reviewed all reports of RCTs of health care interventions and/or processes with
individual randomisation, published July–December 2004 in six major journals. Short, secondary or
interim reports, and Phase I/II trials were excluded. Data recorded were: general RCT details;
inclusion of flow diagram; participant flow throughout trial; reasons for non-participation/
withdrawal; target sample sizes.
Results: 133 reports were reviewed. Overall, 79% included a flow diagram, but over a third were
incomplete. The majority reported the flow of participants at each stage of the trial after
randomisation. However, 40% failed to report the numbers assessed for eligibility. Percentages of
p a r t i c i p a n t s  r e t a i n e d  a t  e a c h  s t a g e  w e r e  h i g h :  f o r  e x a m p l e ,  9 0 %  o f  e l i g i b l e  i n d i v i d u a l s  w e r e
randomised, and 93% of those randomised were outcome assessed. On average, trials met their
sample size targets. However, there were some substantial shortfalls: for example 21% of trials
reporting a sample size calculation failed to achieve adequate numbers at randomisation, and 48%
at outcome assessment. Reporting of losses to follow up was variable and difficult to interpret.
Conclusion: The majority of RCTs reported the flow of participants well after randomisation,
although only two-thirds included a complete flow chart and there was great variability over the
definition of "lost to follow up". Reporting of participant eligibility was poor, making assessments
of recruitment practice and external validity difficult. Reporting of participant flow throughout
RCTs could be improved by small changes to the CONSORT chart.
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Background
Randomised controlled trials (RCTs) are widely acknowl-
edged as the design of choice for evaluating the effective-
ness of health care interventions. However, poor
recruitment and retention of eligible participants is com-
mon and problematic because the sample may fail to be
representative of the relevant population [1], the compa-
rability between treatment arms may be lost, and statisti-
cal power may be reduced [2]. For example, a review that
considered the evidence on participation in RCTs suggests
that treatment effects may be exaggerated by low partici-
pation due to inclusion of participants with a greater
capacity to benefit [3]. In addition to being part of the
good design and conduct of trials, clear and sufficiently
detailed reporting of participant flow is important in
order for readers to assess the generalisability [4], rele-
vance and comparability of trial results.
The CONSORT (Consolidated Standards of Reporting Tri-
als) statement, which consists of a checklist of items to be
addressed, was developed to improve poor reporting [5-
9]. CONSORT specifically addresses the participant flow
through RCTs, providing a template flow diagram for
authors. First published in 1996, the CONSORT state-
ment was subsequently revised to provide greater clarity
and to extend the flow diagram [10,6]. CONSORT is now
supported by organisations including the International
Committee of Medical Journal Editors, the World Associ-
ation of Medical Editors, and the Council of Science Edi-
tors [5]. There is growing evidence that CONSORT has
improved the quality of RCT reports [5,6,8,9], although
previous reviews also suggest that problems remain. For
example, Gross et al. (page 3 [7]) found "sporadic and
incomplete reporting of the recruitment process in many
RCTs"; Devereaux et al. (page 384 [5]) found "suboptimal
reporting" of 11 key methodological factors even among
journals supporting CONSORT; Folkes et al. (page 845
[11]) found that "information pertaining to pre-randomi-
zation was often missing or incomplete"; and Mills et al.
(page 485 [12]) found that "even after a revision of the
CONSORT statement and subscription to it by leading
journals, the reporting of key methodological items con-
tinues to be poor".
Previous reviews have focused on: specific aspects of par-
ticipation (such as recruitment or pre-randomization)
rather than the process as a whole [7,11]; reporting of dif-
ferent stages of participation without assessing (or with
only limited assessment of) the flow of participants
through the trial [5,6,9]; and almost exclusively on trial
reports published prior to the revised CONSORT state-
ment and flow diagram in 2001. Evaluating reports pub-
lished in 2004 (i.e. well after the publication of the revised
CONSORT statement), the present review updates these
findings. It aims to assess the adequacy of reporting of
participant flow through RCTs (from the point of eligibil-
ity assessment to the primary analysis), and the levels of
such participation, in general and in comparison with
sample size targets. By focusing on high quality journals
with wide readerships, this review aims to assess the state
of the art in recruitment, retention and reporting of those
activities.
Methods
Literature search
We searched Medline for all reports of RCTs published
between July and December 2004 in six major journals:
Annals of Internal Medicine, Annals of Surgery, British Medi-
cal Journal (BMJ), The Journal of the American Medical Asso-
ciation (JAMA), The Lancet, and The New England Journal of
Medicine (NEJM). These journals were selected for their
high quality and influence. They were also chosen to span
both medicine and surgery, capturing the variation in
recruitment and retention challenges facing different
fields of enquiry, and reflecting our particular interest in
trials of surgery. We used the standard RCT filter [13], lim-
ited to trials involving human participants. One reviewer
screened all titles and abstracts for relevance and a second
independently crosschecked a sample of 50%. Discrepan-
cies were resolved through discussion of the full paper.
Inclusion/Exclusion criteria
We included all Phase III RCTs of interventions designed
to improve health outcomes and/or processes, in which
randomisation was at the individual level. Phase III trials
were defined as those conducted in a clinical setting, with
patients representative of normal referrals to that setting,
and with the aim of estimating intervention effectiveness.
Cluster and medical education trials were excluded, as
were short, secondary or interim reports, and Phase I and
II trials. Compared to Phase III trials, Phase 1 and II trials
make different demands with regards to recruitment and
retention, typically requiring smaller sample sizes, includ-
ing a larger number of treatment arms varying in dosage,
using shorter term outcomes, making greater use of
sequential testing methods, and aiming to establish the
treatment effect in ideal conditions. Although we did not
exclude studies where the report failed to state explicitly
that it was Phase III, we did exclude those that were explic-
itly labelled Phase I/II. Where there was any lack of clarity,
at least one other team member was consulted by the
reviewers. In total, eleven Phase II trials were excluded
(Figure 1), primarily because they were concerned with
efficacy or dose finding.
Data extraction
For each paper, two independent reviewers extracted data
using a standardised form (papers were divided between
three reviewers: MT, IdS and ZT. Each paper was read by
two of the three reviewers). Disagreements were resolved
by consensus in discussion with a third party (depending
on the nature of the disagreement, one or more of the fol-Trials 2009, 10:52 http://www.trialsjournal.com/content/10/1/52
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lowing authors was consulted on the basis of their area of
expertise: SB, CM, JD and TP). For each included trial, the
following information was recorded: general trial details
(number and nature of interventions, number of centres);
inclusion of a complete or partially complete revised
CONSORT flow diagram; data on participant flow
throughout the trial (extracted from text, tables and dia-
grams); reasons for non-participation and withdrawal;
and data on target sample sizes according to a priori power
calculations.
Analysis
There are four key stages of an RCT: eligibility assessment,
randomisation, treatment and outcome assessment. Since
data were often skewed, percentages progressing from one
stage to the next were reported as median rates (with inter-
quartile ranges – IQR). Each study made an equal contri-
bution to these statistics, irrespective of the overall sample
size. To allow comparability across studies, we considered
rates of outcome reporting at the first post-treatment
assessment. For trials including details of an a priori sam-
ple size calculation, median rates of participation were
also calculated at each stage of the trial in relation to the
sample size required to provide an adequately powered
analysis. Associations between trial characteristics and lev-
els of participation were investigated using Mann-Whit-
ney (for characteristics with two levels), Kruskal-Wallis
(three or more unordered levels) or trend tests (three or
more ordered levels) [14]. All statistical analyses were
conducted using Stata 9 statistical software (StataCorp,
College Station, Tx, 2005).
Results
Profile of RCT reports
The search identified 579 potential papers. A total of 133
RCT reports were included in this analysis, with most
exclusions due to the absence of randomisation or
because the paper was not a full-length report (Figure 1).
Of the 133 included trials, nearly one-third were pub-
lished in the NEJM, a quarter in The Lancet and around a
fifth in JAMA (Table 1). The majority were two-armed,
multi-centre, parallel group trials, with external funding.
Just over half assessed drug interventions, and there were
similar numbers with active and placebo control arms.
The time from randomisation to the first post-treatment
assessment was obtainable for 129 studies. Of these,
around 20% lasted up to four weeks, a quarter lasted more
than four weeks, just over a quarter lasted more than six
months, and a further quarter lasted more than eighteen
months. Two of the missing studies failed to report this
Flow of papers through the systematic review Figure 1
Flow of papers through the systematic review.
Titles & abstracts 
screened (n=579)
Full articles 
screened (n=174)
Total included n=133
Exclusions (n=405)
Reasons: 
Not RCT (n=308) 
Short report (n=80) 
Cluster RCTs (n=13) 
Secondary/interim report (n=1) 
Phase I or II trials (n=3)
Exclusions (n=41)
Reasons: 
Not RCT (n=8) 
Short report (n=4) 
Cluster RCTs (n=1) 
Secondary/interim report (n=14) 
Phase I or II trials (n=8) 
Medical education trials (n=4) 
Consent not gained pre-   
randomisation (n=2)Trials 2009, 10:52 http://www.trialsjournal.com/content/10/1/52
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information, and two had this information defined by the
outcome (in hospital death and the end of a variable
length counselling programme) and did not provide fur-
ther details. This variable is a little inconsistent in its defi-
nition. Some studies have a defined follow-up
appointment, making it easy to derive this information
from the report. Others follow individuals until they expe-
rience an event (e.g. death) with median follow-up most
commonly reported in those cases.
CONSORT flow diagram
Overall, nearly 50% (64/133) included a complete revised
CONSORT flow diagram, and 31% (41/133) a partial dia-
gram (Table 2). All trials reported in JAMA, BMJ and The
Lancet, and all but one in Annals of Internal Medicine,
included at least a partial CONSORT diagram. However,
within Annals of Surgery and NEJM at least half of trials
failed to report any form of CONSORT flow diagram.
Figure 2 presents a revised CONSORT diagram of the lev-
els of reporting for the whole process of participant flow.
Reporting was far better after the point of randomisation
than before. Trials providing only partial CONSORT dia-
grams most commonly omitted data from the eligibility
and recruitment phases of the trial. Only just over half the
trials reported the numbers excluded during these phases.
Reasons for exclusions were poorly reported with only
around 50% reporting the number of individuals not
meeting the inclusion criteria and 50% reporting the
number refusing to participate. All trials reported the total
Table 1: Characteristics of the 133 included RCT reports
Trial characteristic Number of Included RCT Reports (%)
Journal NEJM 39 (29.3)
Lancet 31 (23.3)
JAMA 25 (18.8)
BMJ 15 (11.3)
Annals of Internal Medicine 13 (9.8)
Annals of Surgery 10 (7.5)
Sample Size <200 33 (24.8)
200–449 37 (27.8)
450–749 31 (23.3)
750+ 32 (24.1)
Centres Multiple 95 (71.4)
Single 38 (28.6)
Study Design Parallel 125 (94.0)
Factorial 5 (3.8)
Crossover 3 (2.3)
Number of Arms Two 103 (77.4)
Three 14 (10.5)
Four 12 (9.0)
Five 2 (1.5)
Six 2 (1.5)
Interventions Drug 68 (51.1)
Surgery 21 (15.8)
Allied/Complementary Medicine 20 (15.0)
Othera 24 (18.1)
Nature of Control Arm Active Control 63 (47.4)
Placebo Control 70 (52.6)
Funding Source Externalb 123 (92.5)
Internal/Not statedc 10 (7.5)
a For example, care management, patient education, radiotherapy or mixed interventions
b For example, pharmaceutical companies, government agencies, charities etc.
c For example, hospital department where trial took place; no additional external funding obtainedTrials 2009, 10:52 http://www.trialsjournal.com/content/10/1/52
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number randomised, the majority (93%) the number
allocated per arm, 77% the numbers of participants com-
pleting treatment, 85% completing follow-up, and 96%
the numbers analysed. Where participants did not com-
plete allocated treatment or primary follow-up, reasons
were given in 88% and 77% of cases respectively.
Recruitment, randomisation and retention rates
Table 3 shows the median rates of progression through
each of the key stages of a trial. Since reporting was varia-
ble (Figure 2), the number of trials contributing data at
each stage varies. The percentages of individuals retained
at each stage of the trials were, in general, high. The big-
gest hurdle to full participation was at the stage of initial
assessment for eligibility, with an average of 30% of
invitees failing to attend and 30% of those attending
found to be ineligible. Of individuals assessed as eligible,
the median percentage randomly allocated to a treatment
arm was 90%, with a quarter of studies reporting 100%
being randomised. Nevertheless, the range was wide, with
a further quarter of studies randomising 77% of eligible
individuals or fewer and the poorest performing trial ran-
domising only 20%. Some 28% of studies (33 of 120 tri-
als providing information) found that at least one patient
did not meet the eligibility criteria after they were ran-
domised. Whilst on average this percentage was minimal,
with 90% of trials reporting less than 2% failing to meet
the eligibility criteria post-randomisation, around 6%
reported rates over 5% and one trial found 25% of partic-
ipants to be ineligible after randomisation.
Seventy studies specifically reported the proportion of eli-
gible individuals refusing  to be randomly allocated to
treatment; whilst the median rate was 5% (IQR 0%–
12%), one study reported as many as 61% refusing ran-
domisation. In general, trials did well at retaining partici-
pants from the point of randomisation through to
outcome assessment. Losses were reported at different
points throughout the trials. Of those randomised a
median of 0% (IQR 0% to 2%) were lost before having
received any of the allocated treatment and 7% (IQR 0%
to 15%) after having received some, but not all, of the
allocated treatment. Again, there were instances where
specific studies performed very poorly in these respects.
For example, in one study 34% of participants were lost
without receiving any of the allocated intervention and in
another, 50% were lost having received only part of the
treatment. Of those randomised, a median of 93% (IQR
86% to 99%) provided an assessment of outcome (Table
3). Outcome data were often imputed (using different
methods such as last observation carried forward) where
data were missing, which accounts for the fact that in a
quarter of the trials, more participants were included in
the analysis than had their outcome assessed (Table 3).
Where outcome data were available they were always
included in the analysis. There was considerable difficulty
in extracting data about losses to follow-up because of dif-
ferent interpretations of what was meant by "lost to fol-
low-up".
Extent to which trials met sample size targets
Most of the trials (112/133; 84%) reported a sample size
calculation. The power and significance levels used in
these calculations varied across trials, although all were
reported to be 80% or greater and 5% or less respectively.
In addition, some trials inflated the required sample size
in order to allow for potential dropouts. Where this was
reported, the target sample size (that is, the uninflated
estimate) was recorded and used in the percentages
below. Relative to the target sample size, the majority of
trials either met or exceeded their goal across all stages of
recruitment and retention (Table 4). Trials initially
assessed a median of 230% of their target number, identi-
fied as eligible a median of 130%, and randomised a
median of 110% of the required sample size. Trials also
tended to meet their sample size targets right through to
Table 2: Trial reports providing a revised CONSORT diagram
Journal Yes completely (%) Yes partially (%) No (%)
JAMA (n = 25) 20 (80.0) 5 (20.0) 0
Annals Int. Med. (n = 13) 10 (76.9) 2 (15.4) 1 (7.7)
BMJ (n = 15) 10 (66.7) 5 (33.3) 0
Lancet (n = 31) 16 (51.6) 15 (48.4) 0
NEJM (n = 39) 7 (17.9) 10 (25.6) 22 (56.4)
Annals Surgery (n = 10) 1 (10.0) 4 (40.0) 5 (50.0)
Total (n = 133) 64 (48.1) 41 (30.8) 28 (21.1)Trials 2009, 10:52 http://www.trialsjournal.com/content/10/1/52
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CONSORT diagram of reporting of participant flow Figure 2
CONSORT diagram of reporting of participant flow.
aFor example, logistical reasons or refusal by patient’s doctor to allow participation 
79 (59.4%) trials reported 
number assessed for eligibility 71 (53.4%) reported number excluded overall 
68 (51.1%) reported number not meeting 
inclusion criteria 
75 (56.4%) reported number refusing to 
participate 
67 (50.4%) reported number with other reasons 
for exclusion
a Randomisation 
133 (100.0%) reported 
total number randomised
Enrolment 
103 (77.4%) reported number who did not complete allocated 
intervention per arm 
Reasons: In 76/103 studies some participants did not complete their 
allocated intervention and of these, 67 (88.2%) reported reasons.   
113 (85.0%) reported number who did not complete primary follow-up 
per arm   
Reasons: In 95/113 studies some participants did not complete 
primary follow-up and of these, 73 (76.8%) reported reasons.
124 (93.2%) reported number allocated per arm 
110 (82.7%) reported number who did not receive any of their allocated 
intervention in each arm. 
Reasons: In 50/110 studies some participants did not receive their 
allocated intervention and of these, 36 (72.0%) reported reasons. 
Allocation 
Follow-Up 
128 (96.2%) reported number analysed  
Analysis 
133 trials included in review  Trials 2009, 10:52 http://www.trialsjournal.com/content/10/1/52
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the point of outcome assessment (median = 100%), with
three quarters of the trials assessing at least 92% of the tar-
get number of participants at outcome. Whilst these aver-
age figures are high, there remain a number of trials failing
to achieve the necessary sample size. For example, 21% of
trials reporting a sample size calculation failed to achieve
adequate numbers at randomisation, and 48% at out-
come assessment. Moreover, the worst performing trials
in this respect fell substantially under target with one trial
randomising only 43% of the required number and
another assessing only 36% at outcome.
Potential explanatory variables
Table 5 presents the results of an exploratory analysis
investigating associations between recruitment and reten-
tion rates and trial characteristics. While there is evidence
of an association between study size and the proportion
of people screened who were found to be eligible to par-
ticipate (p = 0.026), there is no simple pattern to the rela-
tionship. Two arm trials were found to assess outcome in
a higher proportion of those randomised when compared
to trials with three or more arms (p = 0.0035). Also, sur-
gery trials were found to assess outcome in a higher pro-
portion of those randomised when compared to studies of
other treatment approaches (p = 0.014). Studies funded
by government or charities randomised a lower propor-
tion of those screened as eligible compared to studies
receiving industry funding or which were internally
funded (p = 0.048). There was no convincing evidence of
differences in recruitment and retention between multi-
Table 3: Reported rates of participant flow through the trial (reported as median rates across studies)
Current stagea Next stagea Number of studiesb Median progressing to 
next stage
First and third 
quartiles
Minimum and 
maximum
Invited to eligibility 
assessment
Attended eligibility 
assessment
13 70% 44%, 96% 15%, 100%
Attended eligibility 
assessment
Found to be eligible 71 70% 49%, 88% 6%, 100%
Found to be eligible Randomised to a 
treatment arm
75 90% 77%, 100% 20%, 100%
Randomised to a 
treatment arm
Outcome assessed 113 93% 86%, 99% 49%, 100%
Outcome assessed Included in analysis 111 100% 100%, 103%c 100%, 202%c
a 'Current stage' denotes the denominator and 'Next stage' the numerator for the percentage progressing to next stage within each study
b Relates to the number of studies providing relevant data
c In some instances missing outcome data were imputed, hence percentages greater than 100% are possible here
Table 4: Reported rates of participant flow through the trial as a percentage of the number required by the reported sample size 
calculation
Number of studiesa Median % of sample size required First and third quartiles Minimum and maximum
Invited to screening 12 410% 288%, 951% 131%, 2549%
Attend screening 62 230% 132%, 379% 83%, 2361%
Eligible 58 130% 108%, 160% 72%, 431%
Randomised 106 110% 100%, 128% 43%, 213%
Outcome assessed 94 100% 92%, 111% 36%, 158%
In analysis 102 103% 98%, 117% 43%, 169%
7 studies which stopped early having demonstrated a benefit of treatment are excluded from these analyses
a Relates to the number of studies providing relevant data
Note: the α (significance) and 1-β (power) levels used in each trial's sample size calculation may varyTrials 2009, 10:52 http://www.trialsjournal.com/content/10/1/52
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centre and single-centre studies, or between studies with
active and placebo controls.
Discussion
The majority of 133 trials published in six high quality
journals during 2004 reported the flow of participants at
each stage of the trial after the point of randomisation
(over 75% for each stage). The percentages of individuals
retained at each stage of the trials were high, with the
median percentage of those eligible randomised, those
randomised assessed at outcome, and those assessed
included in the analysis, all being above 90%. On average,
100% of trial participants received at least part of their
allocated intervention and 93% received it all. However,
percentages of patients reported up to the point of ran-
domisation were less impressive, with 40% failing to
report the numbers assessed for eligibility, and similar
numbers failing adequately to report reasons for exclu-
sions. A small proportion of trial reports had very poor
rates of reporting and/or recruitment and retention,
despite the fact that they were published in high quality
journals.
Overall, this review supports the growing body of evi-
dence that the CONSORT statement has improved report-
ing of RCTs [5,6,8,9]. Comparison of the present sample
with a similar review of trial reports published in 1998 [6]
shows numbers of reports including at least a partial dia-
gram increasing from around 50% in the previous review
(139 of 279 reports) to almost 80% here (105 of 133
reports). The NEJM continues to contribute a substantial
proportion without any flow diagram (44%), although
Table 5: Associations between recruitment and retention rates and trial characteristics
Screened and eligible Eligible and randomised Randomised and outcome assessed
Factor & level Median IQR Number of studies Median IQR Number of studies Median IQR Number of studies
Study size
<200 78 63, 95 25 90 79, 100 26 92 86, 94 32
200–449 71 56, 95 18 93 78, 99 21 92 86, 99 29
450–749 51 33, 64 15 86 66, 97 15 93 84, 98 23
750+ 71 41, 80 13 91 85, 100 13 97 89, 100 29
p = 0.026 p = 0.99 p = 0.24
Number of arms
2 72 48, 93 56 90 78, 100 59 94 88, 99 89
3+ 68 51, 79 15 89 70, 97 16 86 76, 94 24
p = 0.33 p = 0.75 p = 0.0035
Multi-centre?
Yes 75 42, 86 44 92 73, 99 47 94 85, 99 79
No 64 50, 94 27 87 78, 100 28 93 88, 96 34
p = 0.91 p = 0.70 p = 0.64
Treatment focus
Drug 71 53, 86 29 94 73, 100 30 94 86, 99 56
Surgery 75 48, 99 10 89 63, 100 10 99 92, 100 17
Allied 67 50, 88 17 91 81, 99 18 90 85, 94 18
Other 64 44, 86 15 86 79, 93 17 92 84, 96 22
p = 0.89 p = 0.56 p = 0.014
Control
Active 70 51, 86 30 88 74, 95 32 92 85, 98 52
Placebo 68 49, 88 41 94 77, 100 43 93 86, 99 61
p = 0.82 p = 0.24 p = 0.46
Time to assessment
0 to 4 weeks 8 33, 86 10 83 63, 94 11 99 93, 100 26
>4 weeks to 6 months 7 51, 78 23 91 81, 100 24 92 87, 94 30
>6 to 18 months 74 40, 93 20 94 72, 99 21 88 79, 98 31
>18 months 75 63, 93 16 91 83, 100 16 95 86, 100 23
p = 0.087 p = 0.242 p = 0.075
Funding
Pharma 74 54, 93 28 94 83, 100 29 93 85, 99 56
Government/charity 67 48, 86 38 85 70, 97 40 93 86, 96 49
Internal/unstated 56 51, 56 5 98 94, 100 6 95 91, 100 8
p = 0.51 p = 0.048 P = 0.50
P values were obtained from Mann-Whitney tests (for characteristics with two levels), Kruskal-Wallis tests (three or more unordered levels) or 
trend tests (three or more ordered levels)Trials 2009, 10:52 http://www.trialsjournal.com/content/10/1/52
Page 9 of 12
(page number not for citation purposes)
this percentage was lower than previously (92%) [6]. The
NEJM was the last of the five journals to accept the CON-
SORT statement officially, in January 2004. It is likely,
therefore, that some papers accepted for publication in
the NEJM prior to adoption of the CONSORT statement
were included in this review. It is also possible that some
reports omitted a CONSORT flow diagram in accordance
with the CONSORT guidelines, which state that it may be
unnecessary to include a diagram for simple trials with no
losses to follow up or exclusions. However, it seems likely
that this would only explain, at most, a very small minor-
ity of omissions for two reasons: first, for most trials pub-
lished in these journals it is very unlikely that there will
have been no losses to follow up or exclusions; and sec-
ond, as Table 2 suggests, the inclusion of the diagram
seems to depend much more on whether the journal
requires compliance with the whole CONSORT package.
This review demonstrates that whilst the percentage of
papers providing adequate data to complete each element
of the CONSORT flow diagram is higher than pre-CON-
SORT [7,8], there is evidence of continued poor reporting
of pre-randomisation figures [11]. This may partly reflect
greater difficulty in recording data when patients are not
yet part of a trial, and also the view that these are less
important than figures from randomisation onwards.
However, from a practising clinician's viewpoint, these
figures are crucial for judging whether the results of a trial
are generalisable to the patients s/he may treat [1]. If only
a proportion of those patients who fulfil the clinical eligi-
bility criteria are included in the trial, then there is scope
for trial participants to be unrepresentative of the popula-
tion of eligible patients as a whole. This may allow impor-
tant differences to arise between the trial participants and
patients seen in clinical practice who fit the clinical
description of trial participants.
In terms of percentages of participants retained at each
stage of an individual trial, we found that, on average,
only 70% of those invited to screening attended. Only 13
studies reported these data, but this suggests that many
potentially eligible patients exclude themselves for rea-
sons unknown to the investigators. Potential reasons may
include refusal to attend the initial assessment, to be ran-
domised, or to be involved in research altogether, or may
be related to logistical reasons. In turn, this means that the
true rate of refusal to be randomised (calculated in this
review from the number of eligible patients refusing ran-
domisation and estimated to be on average 5%) may be
higher than observed here and the representativeness of
the final samples may be reduced.
On average 70% of those screened were found to be eligi-
ble, although it was often not clear how many potential
eligible patients did not attend for screening. If eligibility
criteria are appropriate and correctly applied, even very
low eligibility rates do not necessarily indicate poor trial
practice as this will depend on the condition under study.
However, large numbers of exclusions can indicate that
eligibility criteria are too narrow, threatening the general-
isability of the sample. Some reports conflated those not
eligible with participants attending screening who then
declined participation, using informed consent as an eli-
gibility criterion, making it impossible to calculate sepa-
rate eligibility and refusal rates [7]. This lack of clarity is
likely to have contributed to a quarter of trials reporting
100% of eligible individuals being randomised. Such
rates might be plausible for simple placebo-controlled tri-
als, but in pragmatic trials the possibility of coercion or
inadequate information cannot be ruled out.
A strength of this review is that it has used an additional
measure for assessing participation: comparing achieved
participation rates with targets set by prior sample size cal-
culations, although it was not clear whether this was as
originally reported in the protocol. Overall, 84% of trials
reported a sample size calculation – a finding that echoes
a previous review of reports published in 2002 ([12], but
see [15] for evidence that some of the required parameters
of the calculations are often not reported). On average, tri-
als met their sample size targets at all stages of the trial,
including (most crucially) at outcome assessment and
analysis. This was generally achieved by over-recruiting
participants, especially for eligibility assessment. A
median of more than double the target sample size was
assessed for eligibility, with a quarter of trials assessing
almost four times the target. However, 48% of trials did
not reach their targets, albeit only marginally for many (a
quarter achieving 92% or more at outcome assessment).
In general, such shortfalls relate to difficulties in recruiting
study participants rather than losses post-randomisation.
The recruitment and subsequent retention of participants
through a trial will be heavily dependent on the nature of
the study and its interventions as well as the organisation
of the trial. This review found that trials with more than
two arms were slightly worse at retaining participants to
the point of outcome assessment than those with only
two arms, that surgical trials were better at retaining par-
ticipants than other trials, and that government- or char-
ity-funded studies randomised a lower proportion of
those screened as eligible than studies funded by industry
or internally. A previous meta-analysis [16] of acute stroke
trials found that, after adjusting for the stringency of the
eligibility criteria, trials with a large number of study cen-
tres tended to recruit less efficiently than those with fewer
centres.
The degree of retention seen in this review could be an
over-estimate, since poorly recruiting or retaining trialsTrials 2009, 10:52 http://www.trialsjournal.com/content/10/1/52
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will be less likely to be published in such high quality
journals. A recent review [17] of registered (rather than
published) trials found that more than two thirds failed to
reach their recruitment target, although a further quarter
achieved over 80%. Other reviews [18,19] of registered tri-
als have demonstrated a similar percentage of trials failing
to reach targets, but with a wider range of deficiency
among those failing. The most common reason cited was
recruitment difficulties.
There are several limitations to this study. The findings
reflect reporting in the six journals under review, leaving
open the question of the extent to which this reflects
reporting of RCTs in general. While our focus on the six
journals limits the generalisability of our findings, it
should not limit the applicability of our recommenda-
tions. Fuller reporting of pre-randomisation patient flow
will be as informative in specialist journals as in the high
quality general medical journals we reviewed. A further
limitation was the focus on papers published in 2004.
This date was chosen as RCTs from this time period were
likely to be listed on Medline when we started work on
this review and it was not possible to up-date it. As the
CONSORT recommendations for reporting patient flow
in trials have not changed since 2004, we believe that our
findings are likely to be a true reflection of current report-
ing in high quality journals. There is also the question of
whether the reporting in the journals really reflects what
happened in the course of these RCTs. There is evidence,
for example, that some important methodological steps
may be undertaken in trials but not reported [20]. It is also
possible that trials with poorer participation may be less
likely to report figures for participant flow. Hence our
recruitment and retention rates may be over-estimates. We
made no attempt to trace any missing information or data
from RCTs, since the aim was to assess the reporting of tri-
als, but this would be an important aim for future
research.
With respect to the CONSORT guidelines, there are rec-
ommendations that can be made on the basis of the find-
ings of this review. We would propose that additional
boxes be included in the flow diagram for the number
invited to attend initial assessment for eligibility and the
number not attending following such an invitation, where
this is possible (see Figure 3). Ideally, the latter should
also include a list of reasons so that refusals to be ran-
domised that occur at this point can be determined. We
would also suggest that informed consent be kept separate
from the eligibility criteria. We recognise that it will not
always be possible to provide all these figures even when
a good data management system is in place. For example,
where potential participants are invited to an eligibility
assessment through posters or newspaper adverts, it will
not be possible to provide a figure for the total number
who read the advert. However, their inclusion should be
advocated wherever possible to enable better assessment
of generalisability and estimation of a true refusal rate for
an individual trial. They would also be useful for manage-
ment of recruitment during trial operation.
The CONSORT flow diagram contains a single box
labelled "follow-up" in which authors are required to
state the number "lost to follow-up" and "discontinued
intervention" (with reasons). The definition of "lost to
follow up" varied considerably in these papers. Our inter-
pretation of "lost to follow-up" is any participant who is
not assessed on the primary outcome irrespective of
whether or not they complete their allocated intervention,
but these two events can happen in a number of combina-
tions (e.g. a participant might fail to complete their allo-
cation and their outcome assessment or might complete
their allocation but fail to be outcome assessed etc.).
These two terms are not used consistently by authors,
making it difficult to be certain at what point in the trial a
participant was lost. "Lost to follow-up" could be replaced
with "number not completing primary outcome assess-
ment" (Figure 3). Details of those who "discontinued
intervention" may serve better as a separate box related to
allocation violations, which would precede outcome
assessment in the natural flow of participants through a
trial. It could be reported in the text, but since such infor-
mation is important in assessing to what extent the esti-
mated effectiveness of the intervention might be under- or
overestimated, it is useful to have in the CONSORT dia-
gram. Greater clarity over the definition of "lost to follow
up" would be helpful.
Finally, there is currently no place within the CONSORT
diagram for those found to be ineligible after randomisa-
tion. Such individuals are sometimes classed as "lost to
follow-up" and excluded from the analysis. Although usu-
ally a small number, it is perhaps clearer to report such
ineligibles in the text of a trial report or as a footnote to
the CONSORT diagram, but to fully report reasons for
exclusions from the primary analysis in the diagram.
Conclusion
This review provides evidence of good reporting of partic-
ipant flow after randomisation in RCTs published in six
major journals. However, reporting of participant eligibil-
ity was poor, with only two-thirds of the reports including
a complete CONSORT flow chart, and few RCTs providing
sufficient information, even where it would be easy to do
so, to allow judgement of the trial's generalisability to
patients in clinical practice. In addition, there was great
variability in the definition of "lost to follow-up" and con-
sequently its impact on data analysis. Assessing the ade-
quacy of participation in trials is an important component
of monitoring the quality of trial results because of theTrials 2009, 10:52 http://www.trialsjournal.com/content/10/1/52
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Proposed revised CONSORT flow diagram Figure 3
Proposed revised CONSORT flow diagram.
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impact that recruitment and retention difficulties can
have on a trial's representativeness and the comparability
of its treatment arms. Even in high quality journals there
remain trials with very poor recruitment and retention
rates and poor reporting. The inclusion of a small number
of additional data items relating to eligibility and loss to
follow-up would further improve the CONSORT flow
chart and enable better evaluation of recruitment and
retention in published trials.
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